2003, Number 1
<< Back Next >>
Rev Mex Cardiol 2003; 14 (1)
Letter to the editor
Menéndez-Conde SM
Language: Spanish
References: 7
Page: 26-27
PDF size: 44.47 Kb.
Text Extraction
No abstract
REFERENCES
Luque CAF, Eguia BA. La ruptura de mitos y la consolidación de realidades. Análisis preliminar del Heart Protection Study. Rev Mex Cardiología 2002; 13: 67-70.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
The Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
West of Scotland Coronary Prevention Study Group: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/Tex. Caps. JAMA 1998; 279: 1615-1622.
Full text